ARTA
CBIO

A.R.T. Advisors’s Crescent Biopharma CBIO Stock Holding History

A.R.T. Advisors’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-359
Closed -$190K – 425
2019
Q4 		$190K Buy
+359
New +$194K 0.01% 1164
2018
Q3 		– Sell
-271
Closed -$437K – 1501
2018
Q2 		$437K Buy
+271
New +$466K 0.02% 971
2014
Q4 		– Sell
-141
Closed -$97K – 1499
2014
Q3 		$97K Buy
+141
New +$114K ﹤0.01% 1207

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

A.R.T. Advisors's CBIO Position: Q1 2020 in Review

A.R.T. Advisors sold out of Crescent Biopharma (CBIO) in Q1 2020, closing a stake of 359 shares — an estimated $190K sold.

A.R.T. Advisors first reported a position in CBIO in Q3 2014 and held it in 3 quarters. The position peaked at $437K in Q2 2018. 76 funds tracked by Wall St. Rank hold CBIO as of Q1 2020.

  • A.R.T. Advisors reported no remaining Crescent Biopharma position as of Q1 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 359 Crescent Biopharma shares in Q1 2020, an estimated $190K.
  • A.R.T. Advisors first reported a position in Crescent Biopharma in Q3 2014 and held it in 3 quarters.
  • A.R.T. Advisors's Crescent Biopharma position peaked at $437K in Q2 2018.
  • 76 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.